Media Hub

View the Latest Content of the Innate Killer Summit

Innate Killer Magazine, First Edition

Capture1
capture22

Discover exclusive insight provided by Beacon Targeted Therapies & 5 insightful interviews with: 

  • Jeffrey Miller, Professor, University of Minnesota
  • Emily Mace, Assistant Professor, Columbia University in the City of New York
  • Nick Huntington, CSO, oNKo-Innate Pty Ltd
  • Allen Feng, CSO, HebeCell Corp.
  • Yu-Kyeong Hwang, SVP & Head of Research & Development, Green Cross LabCell

Exclusive Speaker Interview: Nick Huntington

Nick Huntington, CSO

oNKo-Innate Pty Ltd

Preview:

What do you feel is the biggest challenge with the development of cell therapies?

The complexity of dealing with a unique living product each time creates several logistical challenges, especially in the setting of autologous cell therapies. Thus, the challenge lies in standardizing and streamlining a cell therapy approach without compromising the efficacy.

Exclusive Speaker Interview: Patrick Soon-Shiong

Patrick Soon-Shiong, Chairman & CEO

NantKwest

Preview:

How and to what capacity are you involved with developing NK cell therapies?

NantKwest develops our universal, off-the-shelf natural killer cell platform. This has been engineered to express a high-affinity CD16 for targeted antibodydependent cellular cytotoxicity (ADCC) in combination with IgG1 monoclonal antibodies. These haNK cells are in phase II trials in merkel cell cancer as part of a combination therapy. Cells also have been engineered to express chimeric antigen receptors (CARs) against various tumor antigens. NantCell is focused on the development of a bispecific NK and T cell activation molecule (N-803), which consists of an IL-15 / IL-15 receptor alpha complex that is linked to an IgG1 Fc (a ligand of CD16). This fusion protein has demonstrated an ability to activate and expand NK and CD8+ T cell populations without expanding regulatory T cell populations. N-803 is currently being studied in combination with BCG in a phase II trials in BCG-unresponsive non-muscle invasive bladder cancer, as well as and in combination with anti-PD-1 antibodies in NSCLC and other solid tumors. In addition, NantCell also is further modifying this IL-15-based fusion protein to target additional molecules, such as PD-L1....

Development of novel NK cell-specific chimeric antigen receptors to improve anti-tumor activity.


Dan S.Kaufman at University of California, School of Medicine

image

Tumour-mediated NK priming for cancer immunotherapy.


Mark Lowdell at University College London

Mark Lowdell

Engineering NK cells to target the inhibitory solid tumor microenvironment.

Robin Parihar at Baylor College of Medicine

Robin Parihar

NKTR-255: Accessing The Immunotherapeutic Potential of IL-15 for NK Cell Therapies.


Saul Kivimäe at Nektar Therapeutics

Saul Kivimae